TIL therapy relies on the ex vivo expansion of polyclonal, tumour-resident lymphocytes obtained from resected tumour tissue, followed by lymphodepletion of the patient and reinfusion of the expanded TIL product (often with systemic interleukin-2 support) (131, 132) (Figure 6). The gene discussed is IL2; the disease is neoplasm.